$4m grant not to be sniffed at as Mucosis looks to advance intranasal RSV vaccine
Mucosis has been awarded a Wellcome Trust grant of €3.7m ($4m) to help develop a Respiratory Syncytial Virus (RSV) vaccine using its intranasal delivery platform.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs